US FDA Welcomes Variety Of Phase II/III Trial Designs For COVID-19 Therapies, But With Standards

Final guidance on COVID-19 treatment development emphasizes need for clinical endpoints to reflect drug mechanism, patient population, clinical setting and fast-evolving standard of care – with a cautious embrace of platform and adaptive designs.